KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study. PMID 36401761 · Dermatol Ther (Heidelb) · 2023-Jan The study is a phase 3 randomized trial with a drug intervention (upadacitinib) and reports efficacy results. However, it is not an oncology study; it evaluates atopic dermatitis, a chronic inflammatory skin disease. Additionally, the primary efficacy endpoints are clinical response rates (EASI 75/90, vIGA-AD 0/1, WP-NRS), not time-to-event outcomes such as OS, PFS, DFS, or survival analyses.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature. PMID 36399521 · Expert Rev Anti Infect Ther · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study. PMID 36381249 · J Orthop Translat · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Can transcranial photobiomodulation improve cognitive function? A systematic review of human studies. PMID 36371017 · Ageing Res Rev · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
B cell depletion and inhibition in systemic lupus erythematosus. PMID 36342225 · Expert Rev Clin Immunol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). PMID 36328033 · Lancet Gastroenterol Hepatol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis. PMID 36314172 · Aliment Pharmacol Ther · 2023-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. PMID 36271471 · J Bone Miner Res · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma. PMID 36251361 · Am J Hematol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Less is More? First Impressions From COSMIC-313. PMID 36239611 · Cancer Invest · 2023-Jan The record is a commentary on the first results of a phase 3 randomized trial, not the original primary result report. Furthermore, the abstract does not explicitly mention any time-to-event endpoint (OS, PFS, etc.) or its analysis method (Kaplan-Meier, HR).
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 Trial. PMID 36216658 · Eur Urol · 2023-Jan 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis. PMID 36152266 · Adv Ther · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis. PMID 36066323 · J Eur Acad Dermatol Venereol · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO-Peds trial. PMID 36054737 · Diabetes Obes Metab · 2023-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma. PMID 35907001 · Eur Arch Otorhinolaryngol · 2023-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. PMID 36541957 · Blood Adv · 2023-Feb-28 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 3 Figure · 3 Panel · risk visible
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. PMID 36849516 · Nat Commun · 2023-Feb-27 The report is an analysis of acquired resistance mechanisms from a Phase 3 randomized trial but does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR results. It focuses on genomic/biomarker analysis of progression samples.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials. PMID 36840396 · J Eur Acad Dermatol Venereol · 2023-Feb-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Overcoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review. PMID 36979659 · Biomedicines · 2023-Feb-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Author Correction: Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. PMID 36813827 · NPJ Digit Med · 2023-Feb-22 This is a published erratum for an article on a randomized phase III trial in prostate cancer. As an erratum, it is not an original report of trial results. The provided record lacks an abstract or sufficient text to verify human subjects, drug intervention, or a primary time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR). Therefore, it does not meet the criteria for an original formal-result report of a definitive randomized trial with the required endpoint.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care (the ASPIC trial): study protocol for a randomised controlled trial. PMID 36810173 · BMJ Open · 2023-Feb-21 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Lidocaine for Neuropathic Cancer Pain (LiCPain): study protocol for a mixed-methods pilot study. PMID 36810169 · BMJ Open · 2023-Feb-21 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. PMID 35235656 · Clin Infect Dis · 2023-Feb-18 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The effects of royal jelly supplementation on oxidative stress, inflammatory mediators, mental health, cognitive function, quality of life, and clinical outcomes of patients with ischemic stroke: study protocol for a randomized controlled trial. PMID 36797768 · BMC Nutr · 2023-Feb-16 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice. PMID 36426410 · Cancer · 2023-Feb-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer. PMID 36844136 · World J Gastroenterol · 2023-Feb-14 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Subanalysis of Subjective Cognitive Measures From a Phase 2, Double-Blind, Randomized Trial of REL-1017 in Patients With Major Depressive Disorder. PMID 36821775 · Prim Care Companion CNS Disord · 2023-Feb-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. PMID 36383730 · Blood Adv · 2023-Feb-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. PMID 36774155 · Lancet · 2023-Feb-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial. PMID 36773112 · Ann Intensive Care · 2023-Feb-11 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. PMID 36765311 · BMC Cancer · 2023-Feb-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized confirmed 2 Figure · 4 Panel · risk visible
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. PMID 36763878 · Br J Dermatol · 2023-Feb-10 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. PMID 36130300 · Blood · 2023-Feb-09 While the record describes a Phase III randomized trial with a drug intervention (ixazomib) and a time-to-event endpoint (PFS), it is a secondary/post-hoc analysis of MRD dynamics and prognostication, not the original primary efficacy result report of the trial.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. PMID 36798177 · Res Sq · 2023-Feb-08 The study is a prognostic/biomarker analysis from a Phase 3 trial and does not report a primary/key secondary time-to-event efficacy endpoint as required for eligibility.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction to: Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. PMID 36617223 · Clin Infect Dis · 2023-Feb-08 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A systematic review of the comparison between needling (RF-needling, meso-needling, and micro-needling) and ablative fractional lasers (CO2, erbium YAG) in the treatment of atrophic and hypertrophic scars. PMID 36749436 · Lasers Med Sci · 2023-Feb-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. PMID 36739285 · NPJ Breast Cancer · 2023-Feb-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials. PMID 36087303 · Aesthet Surg J · 2023-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Management of Marginal Zone Lymphoma: A Canadian Perspective. PMID 36826096 · Curr Oncol · 2023-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris. PMID 36745367 · J Drugs Dermatol · 2023-Feb-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Precision Effects of Glibenclamide on MRI Endophenotypes in Clinically Relevant Murine Traumatic Brain Injury. PMID 36661464 · Crit Care Med · 2023-Feb-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial. PMID 36520462 · JAMA Ophthalmol · 2023-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Advances in antibody-drug conjugates for gynecologic malignancies. PMID 36484278 · Curr Opin Obstet Gynecol · 2023-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial. PMID 36150450 · Int J Radiat Oncol Biol Phys · 2023-Feb-01 The record describes a Phase II non-randomized radiation therapy trial with a toxicity primary endpoint and a secondary efficacy endpoint (freedom from biochemical/clinical failure) that is not a standard time-to-event endpoint (like OS, PFS, DFS, etc.) nor reported with Kaplan-Meier or HR. It fails on multiple key eligibility criteria: it is not Phase III, not randomized, and lacks a drug intervention.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. PMID 35907513 · Int J Radiat Oncol Biol Phys · 2023-Feb-01 The study is a Phase II randomized trial in prostate cancer with a drug intervention (metformin), but its primary endpoints are anthropometric and metabolic parameters (weight, waist circumference, LDL cholesterol), not time-to-event efficacy outcomes (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). It does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. PMID 35766811 · Rheumatology (Oxford) · 2023-Feb-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities. PMID 37780103 · J Allergy Clin Immunol Glob · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6-35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia. PMID 36880049 · EClinicalMedicine · 2023-Feb 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
CDK4/6 Inhibitors in Advanced HR+/HER2 - Breast Cancer: A Multicenter Real-World Data Analysis. PMID 36876172 · Breast Care (Basel) · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 5 Figure · 5 Panel · risk not_visible
First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis. PMID 36872922 · Liver Cancer · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -